Список литературы

[1] Баймурадова С.М. Патогенез, принципы диагностики, профилактики и терапии синдрома потери плода, обусловленного приобретенными и генетическими дефектами гемостаза. Дис. ... д-ра мед.наук.

[2] Баркагян З.С. и др. Руководство по гематологии. В 2-х томах// М., 1985

[3] Баркагян З.С., Баркагян Л.З., Бишевский К.М. и др. Контроль за противотромботической терапией и коррекция ее побочных эффектов. II Всесоюзная конференция «Поражение сосудистой системы и гемостаза». // Тез. Докл., М., 1983.-394-396 с.

[4] Баркагян З.С., Буевич Е.И., Тимошенко Е.А. Тромбофилия, характеризующая резистентность к антикоагулянтам прямого действия.// Терапевт.арх., 1995.-№7.-с.50-52

[5] Белоусов Ю.Б. Тромболитическая терапия.// Кардиология, 1986.- Т.26- №9.- с.116-118

[6] Бицадзе В.О. Патогенез, принципы диагностики и профилактики осложнений беременности, обусловленных тромбофилией. Дис. ... д-ра мед.наук. - Москва, 2004. - 251 с. (5)

[7] Бицадзе В.О., Макацария А.Д., Хизроева Д.Х., Макацария Н.А., Яшенина Е.В. Тромбофилия как важнейшее звено патогенеза осложнений беременности. Журнал практическая медицина, №5(60), 2012г.; с. 22-30

[8] Гродницкая Е.Э. Роль нарушений обмена фолатов и гомоцистеина в развитии осложнений беременности // Российский вестник акушера- гинеколога - 2010.- Т.10. -№4.- С. 20-24. (7)

[9] Громыко Г.Л., Зубжицкая Л.Б. Особенности течения и исходы беременностей у женщин с антифосфолипидным синдромом // Матер. Всерос. научн.-практ. конф. — Екатеринбург, 1999.

[10] Доброхотова Ю.Э., Сухих Г.Т., Очан Т.Б., Файзуллин Л.З., Джобава Э.М. Генетические факторы тромбофилии и гипергомоцистеинемия при неразвивающейся беременности и начавшемся выкидыше // Российский медицинский журналю -2008.- №1.- С. 42-44. (10)

[11] Журавлева Е.В. Противотромботическая профилактика повторных преэклампсий у женщин с тромбофилией.

[12] Макаров О.В., Озолиня Л.А. Венозные тромбозы в акушерстве и гинекологии. // М., 1998.- 262 с.

[13] Макацария А.Д, Бицадзе В.О., Баймурадова С.М., Долгушина Н.В., Юдаева Л.С., ХизроеваД.Х., Акиньшина С.В. антифософлипидный синдром - иммунная тромбофилия в акушерстве и гинекологии. -М.: «Триада-Х», 2007. - 456 с.(24)

[14] Макацария А.Д., Белобородова Е.В., Баймурадова С.М., Бицадзе В.О. Гиергомоцистеинемия и осложнения беременности. -М: «Триада-Х».- 2005. - 216 с. (21)

[15] Макацария А.Д., Бицадзе В.О. Тробофилические осложнения в

акушерской практике. 2001 с 498-537

[16] Макацария А.Д., Бицадзе В.О., Акиньшина С.В., Тромбоза и

тромбоэмболии в акушерско-гинекологической практике 2007: с.151;1049

[17] Макацария А.Д., Бицадзе В.О., Смирнова Л.М., Акиньшина С.В., Баймурадова С.М. Тромбогеморрагические осложнения в акушерско- гинекологической практике: Рук.для врачей. - М.: ООО «Медицинское

информационное агентство», 2011. - 1056 с. (25)

[18] Макацария А.Д., Бицадзе В.О., Хизроева Д.Х., Макацария Н.А., Яшенина Е.В. Патогенетическое значение антифосфолипидных антител. Журнал практическая медицина, №5(60), 2012г.; с. 9-12

[19] Макацария А.Д., Бицадзе, Акиньшина С.В. Применение низкомолекулярного гепарина в акушерской, гинекологической и онкологической практике // Consilium medicum. - 2005. - Т. 7. - № 7. - С.556­565.

[20] Макацария А.Д., Мищенко А.Л., Бицадзе В.О., Маров С.В. Синдром диссеминированного внутрисосудистого свертывания крови в акушерской практике; 2002; 168-192

[21] Макацария А.Д., Системные синдромы в акушерско-гинекологической клинике; 2010; с 720-57

[22] Панченко В.М., Вопросы патогенеза, клиники и лечения тромбозов и эмболий // Панченко В.И., Колесникова Н.И., Владимирова А.В. - М: ЦОЛИУВ, 1978. - 56 с.

[23] Передеряева Е.Б. Основные принципы ведения беременности и безопасного родоразрешения у женщин с метаболическим синдромом. Дисс.

[24] Прелатов В.А., Глушач И.А. Профилактика артериальных тромбоэмболий // Грудная хирургия, 1997.- №2.- с.140

[25] Стрижаков А.Н., Макацария А.Д., Тимохина Е.В., Баймурадова С.М., Козлова У.А. Клиническое значение приобретенных и наследственных форм тромбофилий в патогенезе синдрома задержки роста плода // Вопросы гинекологии, акушерства и перинатологии. - 2009. - Т. 8. - № 2. - С. 16-21."

[26] Aggarwal PK, Jain V, Jha V. Endothelial nitric oxide synthase, angiotensinconverting enzyme and angiotensinogen gene polymorphisms in hypertensive disorders of pregnancy // Hypertens Res. 2010 May;33(5):473-7.

[27] Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences // Arterioscler Thromb Vasc Biol. 2006 Oct;26(10):2200-7

[28] Alfirevic Z, Roberts D et al. How strong is the association between maternal thrombophilia and adverse pregnancy outcomes. A systematic review. Eur.J. Obstet.Gyn.Reprod.Biol. 2002; 101 (1): 6-14

[29] Alijotas-Reig J, Vilardell-Tarres M. Is obstetric antiphospholipid syndrome a primary nonthrombotic, proinflammatory, complement-mediated disorder related to antiphospholipid antibodies? // Obstet Gynecol Surv. 2010 Jan;65(1):39-45.

[30] Amoroso E.C. Placentation. In:Parker AS, ed. Marshalls Physiology of Reproduction. 3rd ed. London: Longmans, Green and Co. 1952:127-311

[31] APASS Investigators. Antiphospholipid Antibodies and Subsequent Thrombo-occlusive Events in Patients With Ischemic Stroke. JAMA. 2004; 291:576-584

[32] Arnout J. Detection of antiphospholipid antibodies // Thromb. Haemost. — 2003; ISSN 1740 3340 (Suppl): (abstr SY68).

[33] Asherson R.A., Cervera R., Piette J.C., Font J., Lie J.T., Burcoglu A., Lim K., Munoz-Rodriguez F.J., Levy R.A., Boue F., Rossert J., Ingelmo M. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients // Medicine (Baltimore). 1998 May;77(3):195-207.

[34] Asherson RA.

[35] Balta G, Altay C, Gurgey A.PAI-1 gene 4G/5G genotype: A risk factor for thrombosis in vessels of internal organs //Am J Hematol. 2002 Oct;71(2):89-93.

[36] Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the seventh ACCP Conference on antithrombotic and thrombolytic therapy // Chest. 2004;126:627S-643S.

[37] Bauer S, Pollheimer J, Hartmann J et al. Tumor necrosis factor- aipha inhibits trophoblast migration through elevation of plasminogen activator inhibitor-1 in first trimester villous explants cultures. J .Clin.Endocrinol.Metab. 2004; 89 (2): 812-822

[38] Benedetto C, Marozio L, Saslton L, Maula V, Chippa G, Massobrio I. Factor V Leiden and factor II G20210A in preeclampsia and HELLP syndrome // Acta Obstet Gynecol Scand. 2002;81: 1095-1100.

[39] Bick RL, Frenkel EP, Backer WF, Sarode R. Hematological complications in obstetrics, pregnancy, and gynecology // UK, Cambridge University press, 2006. P 604

[40] Bodnar LM, Ness RB, Markovic N, Roberts JM. The risk of preeclampsia rises with increase pregnancy body mass index. Ann Epidemiol 2005; 15: 475-82

[41] Bonnar J, Redman CW, Denson KW. The rol of coagulation and fibrinolysis in preeclampsia. Perspect.Nephrol.Hypertens. 1976; 5:85-93

[42] Bremme K, Ostlund E, Almqvist I, et al. Enhanced thrombin generation and fibrinolytic activity in the normal pregnancy and the puerperium.// Obstet Gynecol. 2001;13: 115-119.

[43] Bremme KA. Hemostatic changes in pregnancy// Ballieres Best Pract Res ClinHaematol. 2003;16: 153-168."

[44] Brenner B, for the LIVE-ENOX Investigators. Efficacy and safety of two doses of Enoxaparin in pregnant women with thrombophilia and recurrent pregnancy loss:the LIVE-ENOX Study [abstract]// Blood. 2002;100:2765:702a.

[45] Brenner B, Hoffman R, Blumenfeld Z et al. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin // Thromb Haemost.

[46] Brenner B, Hoffman R, Blumenfeld Z et al. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin // Thromb Haemost. 2000 May;83(5):693-7."

[47] Brenner B. Haemostatic changes in pregnancy. Thromb. Res. 2004; 114 (5-6): 409-414

[48] Brill-Edwards P, Ginsberg JS, Gent M et al; Recurrence of Clot in This Pregnancy Study Group. Safety of withholding heparin in pregnant women with a history of venous thromboembolism // N Engl J Med.2000 Nov 16;343(20):1439"

[49] Bujold E, Roberge S, Lacasse Y et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta analysis// Obstet Gynecol. 2010 Aug;116(2 Pt 1):402-14.

[50] CAPRIE Steering Committee. A randomized, blinded. Trial of clopidogrel versus aspirin in patients at risk of ischemic events.// Lancet, 1996; 348:1329-1339

[51] Carbillon L., Uzan S. Early treatment with low-dose aspirin is effective for the prevention of preeclampsia and related complications in high-risk patients selected by the analysis of their historic risk factors // Blood 2005 105:902- 903; doi:10.1182/blood-2004-08-3268

[52] Carlin AJ, Farquharson RG, Quenby SM et al. Prospective observational study of bone mineral density during pregnancy: low molecular weight heparin versus control // Hum Reprod. 2004 May;19(5):1211-4.

[53] Cattaneo M. Hyperhomocysteinemia and venous thromboembolism // Semin Thromb Hemost. 2006 Oct;32(7):716-23.

[54] Cervera R, Piette JC, Font J et al.; Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients // Arthritis Rheum. 2002 Apr;46(4):1019-27.55.Chang J, Elam-Evans

[55] Chan P, Brown M, Simpson JM, Davis G. Proteinuria and preeclampsia how mach matters? BJOG 2005; 112(3):280-5

[56] Circulating platelet-derived and placenta-derived microparticles expose Flt-1 in preeclampsia.

[57] Cockell AP, Learmont JG, Redman CW et al. Human placental syncytiotrophoblastmicrovillous membranes impair maternal vascular endothelial function. Br. J. Obstet.Gynaecol. 1997; 104(2): 235-240

[58] Cojocaru I.M., Cojocaru M, Musuroi C, Botezat M. Study of anti-cardiolipin and anti-beta2- glycoprotein I antibodies in patients with ischemic stroke. Rom J Intern Med. 2003; 41(2): 189-204.

[59] Coller B.S. Platelet GPIIb/IIIa antagonist: the first anti-integrin receptor therapeutics.// Clin. Invest., 1997; 99:1467-1471

[60] Coomarasamy A, Honest H, Papaioannou S et al. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review // Obstet Gynecol. 2003 Jun;101(6):1319-32.

[61] Coppola A, Davi G, De Stefano V et al. Homocysteine, coagulation, platelet function, and thrombosis // Semin Thromb Hemost. 2000;26(3):243-54

[62] Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J. Thromb.Haemost .2005; 3 (8): 1800-1814

[63] Coulam CB, Wallis D, Weinstein J, DasGupta DS, Jeyendran RS. Comparison of thrombophilic gene mutations among patients experiencing recurrent

miscarriage and deep vein thrombosis // Am J Reprod Immunol. 2008 Nov;60(5):426-31.

[64] Cunningham FG, Lindheimer MD. Hypertension in pregnancy. New England Journal of Medicine 1992 Apr 2;326(14):927-32.

[65] D'Anna R, Baviera G, Corrado F, Giordano D, De Vivo A, Nicocia G, et al. Adiponectin and insulin resistence in early-and late onset preeclampsia. Br J Obset Gynaecol 2006: 113:1264-1269

[66] De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications // Haematologica. 2002 Oct;87(10):1095-108

[67] de Vries Jlp, Dekker GA, Huijgens PC, et al. Hyperhomcoysteinaemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol.1997;104: 1248-1254.

[68] Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies // J Thromb Haemost. 2005 Feb;3(2):292-9.

[69] Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies // J Thromb Haemost. 2005 Feb;3(2):292-9. (85)

[70] Di Simone N, Meroni PL et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta-2-glycoprotein I. Arthritis Rheum. 2000; 43 (1): 140-150

[71] Di Simone N, Meroni PL, de Papa N et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I // Arthritis Rheum. 2000 Jan;43(1): 140-50.

[72] Dolitzky M, Inbal A, Brenner B et al. A randomized study of thromboprophilaxis in women with unexplained consecutive recurrent miscarriages. Fertil.Steril. 2006; 86: 362

[73] Dossenbach-Glaninger A, van Trotsenburg M, Dossenbach M et al. Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss //Clin Chem. 2003 Jul;49(7):1081-6.

[74] Duckitt K, Harrington D. Risk factors foe preeclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005; 330(7491):565

[75] Eichinger S. Are B vitamins a risk factor for venous thromboembolism? Yes. //J Thromb Haemost. 2006 Feb;4(2):307-8.

[76] Eichinger S. D-dimer testing in pregnancy. // Semin Vasc Med. 2005 Nov;5(4):375-8."

[77] Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant // Cochrane Database Syst Rev. 2005 Apr 18;(2):CD002859.

[78] Fabbro D, D'Elia AV, Spizzo R et al. Association between plasminogen activator inhibitor 1 gene polymorphisms and preeclampsia // Gynecol Obstet Invest. 2003;56(1):17-22."

[79] Fitzpatrick LA, Good A. Micronized progesterone: clinical indications and comparison with current treatments // Fertil Steril. 1999 Sep;72(3):389-97."

[80] Forastiero R, Martinuzzo M. Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome // Lupus. 2008 Oct;17(10):872-7."

[81] Frenkel E.P., Bick R.L. Prothrombin G20210 gene mutation, Heparin cofactor II defects, primary thrombocytopenia, and thrombohemorrhagic manifestations.// Seminars in thrombosis and hemostasis, Porto, 2000

[82] Gando S, Nakanishi Y, Tedo I: Cytokines and plasminogen activator ingibitor-1 in posttrauma disseminated intravascular coagulation: Relationship to multiple organ dysfunction. Crit Care Med 23:1834, 1995

[83] Germain SJ, Sacks GP et al. Systemic inflammatory priming in normal

pregnancy and preeclampsia: the role of circulating

syncytiothrophoblastmicroparticles. J. Immunol. 2007; 178: 5949-56

[84] Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy // Chest. 2001;119: 122S-131S."

[85] Girardi G, Berman J, Redecha P et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J. Clin. Invest.2003; 112(11): p 1644-1654

[86] Glueck CJ, Kupferminc MJ, Fontaine RN, Wang P, Weksler BB, Eldor A. Genetic hypofibrinolysis in complicated pregnancies // Ostetric Gynecol.2001;97: 44-48.

[87] Glueck CJ, Kupferninc NJ et al. Genetic hypofibrinolisis in complicated pregnancies. Obstet. Gynecol. 2001 Jan; 97 (1): 44-8

[88] Goddijn-Wessel TA, Wouters MG, van der Molen EF, et al. Hyperhomocysteinemia: a risk factor for placental abruption or infarction // Eur J Ostet Gynecol Reprod Biol. 1996;66: 23-29.

[89] Govindaiah V, Naushad SM, Prabhakara K et al. Association of parental hyperhomocysteinemia and C677T Methylene tetrahydrofolate reductase (MTHFR) polymorphism with recurrent pregnancy loss // Clin Biochem. 2009 Mar;42(4-5):380-6."

[90] Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy // Blood. 2005 Jul 15;106(2):401-7."

[91] Greet IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review. Blood 2005; 106:401-7

[92] Gris JC, Mercier E et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103 (10): 3695-3699

[93] Gris JC, Mercier E, Quere I et al. Low-molecular-weight heparin versus lowdose aspirin in women with one fetal loss and a constitutional thrombophilic disorder // Blood. 2004 May 15;103(10):3695-9.

[94] Gris JC, Mercier E, Quere I et al. Low-molecular-weight heparin versus lowdose aspirin in women with one fetal loss and a constitutional thrombophilic disorder// Blood. 2004 May 15;103(10):3695-9.

[95] Gris JC, Neveu S, Tailand ML, Courtieu C, Mares P, Schved JF. Use of a lowmolecular weight heparin (enoxaparin) or of a phenformin-like substance (moroxydine chloride) in primary early recurrent aborters with an impaired fibrinolytic capacity // Thromb Haemost. 1995;73: 362-367."

[96] Grosser O., Fruhentwicklung, Eihautbinbung and Placentation des Menschen un der Saugetiere. Munchen: Verlaf von J.F. Bergmann. 1927:74-174

[97] Harkskamp R, Zeeman G. Preeclampsia: At Risk for Remote Cardiovascular Disease. The American Journal of the Medical Sciences 2007. 334(4): 291-295.

[98] Harrison L., Johnson M., Massicotte M.P., Crowther M., Moffat K., Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. // Ann. Intern Med., 1997; 126: 133-136

[99] Hills FA, Abrahams VM, Gonzalez-Timon B et al. Heparin prevents programmed cell death in human trophoblast // Mol Hum Reprod.2006 Apr;12(4):237-43."

[100] Holers VM, Girardi G et al. Complement C3 activation is required for antiphospholipid antibody- induced fetal loss. J. Exp. Med. 2002; 195(2): 211-220

[101] Hsu CD, Witter FR. Urogenital infection in preeclampsia. Int J Gynaecol Obstet 1995; 49:271-5

[102] Huang SJ, Schatz F et al. Regulation of chemokine production in response to pro-inflammatory cytokines in first trimester decidual cells. J. Reprod.Immunol. 2006; 72 (1-2): 60-73

[103] Izci B, Riha RL, Martin SE, Vennelle M, Liston WA, Dundas KS, et al. The upper airway in pregnancy and preeclampsia. Am J Respir Crit Care Med 2003; 167:137-140

[104] James AH, Brancazio LR, Price T. Aspirin and reproductive outcomes // Obstet Gynecol Surv. 2008 Jan;63(1):49-57.

[105] James RM, Gammill H. Insulin resistance in preeclampsia. Hypertension 2006; 47: 341-342

[106] Jensen JT, Burke AE, Barnhart KT et al. Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis // Contraception. 2008 Dec;78(6):451-8. (131)"

[107] Jespersen J. Plasma resistance to activated protein C: an important link, between venous thromboembolism and combined oral contraceptives - a short review. Eur. J. Contracept.Reprod. Health Care 1996; 1:3-11

[108] Jespersen J. Plasma resistance to activated protein C: an important link, between venous thromboembolism and combined oral contraceptives - a short review. Eur. J. Contracept.Reprod. Health Care 1996; 1:3-11

[109] Journal Hypertension in pregnancy; Volume 27 №3 2008, с.237-245

[110] Journal Hypertension in pregnancy; Volume 28 №1 2009, с.13-21

[111] Journal Hypertension in pregnancy; Volume 29 №3 2010, с.350-351

[112] Journal Pregnancy Hypertension 2013; 3(1):44-7

[113] Journal Pregnancy Hypertension; Volume 3 №1 2013, с.28-34

[114] Kaaroud H, Beji S, Guermazi S et al. Bleeding and thrombosis in a patient with econdary antiphospholipid syndrome // Saudi J Kidney Dis Transpl. 2008 Mar;19(2):227-31.

[115] Kelly PJ, Rosand J, Kistler JP et al. Homocysteine, MTHFR 677C->T polymorphism, and risk of ischemic stroke: results of a meta-analysis // Neurology. 2002 Aug 27;59(4):529-36.

[116] Khamashta MA. Hughes syndrome. Antiphospholipid syndrome// Second edition. - Springer. London, 2006. - 598 p.

[117] Kovac M, Mitic G et al. Thrombophilia in women with pregnancy-associated

complications: fetal loss and pregnancy-related venous

thromboembolism∖∖Gynecol.Obstet. Invest. 2010; 69(4): 233-8

[118] Kristen Duckitt ea al. Risk factors for preeclampsia at antenatal booking: systematic review of controlled studies. BMJ Mar. 12, 2005; 330:565

[119] Krone KA, Allen KL, McCrae KR. Impaired fibrinolysis in the antiphospholipid syndrome //Curr Rheumatol Rep. 2010 Feb;12(1):53-7. (140)

[120] Kupferminc MJ, Fait G et al. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy 2001; 20(1): 35-44

[121] Kupferminc MJ, Fait G, Many A, et al. A low molecular weight heparin for the prevention of obstetric complications in women with thrombophilia // Hypertens Preg. 2001;20: 35-44.

[122] Kupferminc MJ, Peaceman AM, Aderka D, Wallach D, Socol ML. Solube tumor necrosis factor and interleukin-6 in patient with severe preeclampsia. Obstet Gynecol 1998; 179:80-86

[123] Kupferminc MJ. Thrombophilia and pregnancy. Reprod.Biol.Endocrinol. 2003; 1: 111

[124] Laivuori H, Kaaja R, Koistinen H, et al. Leptin during and after preeclamptic or normal pregnancy: its relation to serum insulin and insulin sensitivity. Metab: Clin Exp 2000;49:259-63

[125] Laivuory H, Kaaja R, Turpeinen U, Viinikka L, Ylikorkala O. Plasma homocysteine levels elevated and inversely related to insulin sensitivity in preeclampsia. Obstet Gynecol 1999; 93: 489-493

[126] Lanir N, Aharon A, Brenner B. Haemostaticmachanisms in human placenta. Best Pract. Res. Clin.Haematol. 2003; 16(2): 183-195

[127] Laude I, Rongieres-Bertrand C, Boyer-Neumann C, et al. Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight // Thromb Haemost. 2001;85: 18-21.

[128] Lepercq J, Conard J, Borel-Derlon A et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies // BJOG. 2001 Nov;108(11):1134-40.

[129] Levi M, van der Poll T. Two-way interactions between inflammation and coagulation. Trends. Cardiovase Med. 2005; 15 (7): 254-259

[130] Lim W. Antiphospholipid antibody syndrome // Hematology Am Soc Hematol Educ Program. 2009:233-9.

[131] Lockwood CJ, Huang SJ et al. Decidual Haemostasis, Inflammation and Angiogenesis in Preeclampsia. Seminars in Thromb.Hemost. Vol 37, number 2, 2011: 158-163

[132] Lockwood CJ, Toti P et al. Thrombin regulates soluble fms-like tyrosine kinase-1 (s-Flt-1) expression in first trimester deciduas: implications for preeclampsia. Am. J. Pathol. 2007; 170(4): 1398-1405

[133] Lopez-Jaramillo P., Casas J.P., Serrano N. Preeclampsia: from epidemiological observations to molecular mechanisms // Braz. J. of Med. And Biol. Research. -2001; 34: 1227-1235

[134] Lyall Fiona, Belfort Michael, editors. Preeclampsia . Etiology and clinical practice. Cambridge, UK: Cambridge University Press; 2007.

[135] Mak A, Cheung MW, Cheak AA, Ho RC. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression // Rheumatology. 2010 Feb;49(2):281-8. (154)"

[136] Marlar RA, Husain S. The enigmas of the lupus anticoagulant: mechanisms, diagnosis, and management // Curr Rheumatol Rep. 2008 Jan;10(1):74-80

[137] Maternal mortality--United States, 1982-1996. Morbidity and Mortality Weekly Report (MMWR) 1998 Sep 4;47(34):705-7.

[138] McCully KS. Chemical pathology of homocysteine. IV. Excitotoxicity, oxidative stress, endothelial dysfunction, and inflammation // Ann Clin Lab Sci. 2009 Summer;39(3):219-32. (160)"

[139] Mehdi AA, Uthman I, Khamashta M. Antiphospholipid syndrome: pathogenesis and a window of treatment opportunities in the future // Eur J Clin Invest. 2010 May;40(5):451-64. (161)"

[140] Meigs JB, Wilson PW, Fox CS, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006; 91:2906-12

[141] Mello G, Parretti E, Fatini C et al. Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women // Hypertension. 2005 Jan;45(1):86 91

[142] Mello G., Parretti E. et al; Thrombophilia is significantly associated with severe preeclampsia: results of a large-scale, case-controlled study. Hypertension 2005; 46: 1270-1274.

[143] Meltzer ME, Doggen CJ, de Groot PG et al. The impact of the fibrinolytic system on the risk of venous and arterial thrombosis // Semin Thromb Hemost. 2009 Jul;35(5):468-77.

[144] Meroni PL, Rashi E et al. Endotelial cell activation by antiphospholipid antibodies. Clin.Immunol., 2004; 112 (2): 169-74

[145] Messerli M, May K et al. Feto-maternal intervactions in pregnancies: placental microparticles activate peripheral blood monocytes. Placenta 2010; 31 (2): 106-112

[146] Meziani F, Tesse A et al. Shed membrane particles from preeclamptic women generate vascular wall inflammation and blunt vascular contractility. Am. J. Pathol. 2006; 169 (4): 1473-1483

[147] Mittendorf R, Lain KY, Williams MA, Walker CK. Preeclampsia. A nested, case-control study of risk factors and their interactions. J Reprod Med 1996; 41:491-6

[148] Moffett A, Loce C. Immunology of placentation in eutherian mammals. Na Rev Immonol 2006; 6: 584-594

[149] Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109: 3161-3172

[150] Mousa SA. Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: emerging links // Semin Thromb Hemost. 2007 Jul;33(5):524-33. (166)

[151] National Institute for Clinical Excellence. Why Women die. Report on Confidential Enquiries into Maternal Deaths in the United Kingdom, 1997-1999. London:RCOG Press; 2001

[152] Nelen WLDM, Blom HJ, Steegers EAP, den Heijer M, Eskes TKAM. Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis // Fertil Steril. 2000;74: 1196-1199.

[153] Ness RB, Roberts JM. Heterogeneous causes constituting the single syndrome of pre-eclampsia: a hypothesis and its implications. Am J Obstet Gynecol 1996; 175: 1365-1370

[154] NICE NNational Institute for Health and Clinical Excellence clinical guideline 107 Hypertension in pregnancy: the management of hypertension disorders during pregnancy. 2010

[155] Nielsen CM, Hansen K, Andersen HMK, Gerstoft J, Vestergaard BF. A biotin-avidin-amplified inhibition enzyme immunoassay for detection of CMV antibodies in human serum. J Virol Methods 1987;16:195-208

[156] Nizzi FA Jr, Kaplan HS. Protein C and S deficiency // Semin Thromb Hemost.1999;25(3):265-72.

[157] Noble LS, Kutteh WH, Lashey N et al. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin // Fertil Steril. 2005 Mar;83(3):684-90.

[158] Norgard B, Puho E, Czeizel AE et al. Aspirin use during early pregnancy and the risk of congenital abnormalities: a population-based case-control study // Am J Obstet Gynecol. 2005 Mar;192(3):922-3.

[159] Palomo IG, Segovia FM, Alarcon ML et al. An insight into the pathophysiology of thrombosis in antiphospholipid syndrome // Front Biosci. 2007 May 1;12:3093-103.(177)

[160] Pandey M, Mantel GD, Moodley J. Audit of severe acute morbidity in hypertensive pregnancies in a developing country. J Obstet Gynecol 2004; 24:387­391

[161] Pieroni F, Loureerio DM, Morelli VM et al. Cytokine gene variants and venous thrombotic risk in the BRATROS (BRAZILIAN THROMBOSIS STUDY) // Thromb Res. 2007;120(2):221-9.

[162] Quenby S, Mountfield S, Cartwright JE et al. Effects of low-molecular- weight and unfractionated heparin on trophoblast function // Obstet Gynecol. 2004 Aug;104(2):354-61.

[163] Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies) // BMJ. 1997 Jan25;314(7076):253-7.

[164] Rand JH, Wu XX, Quinn AS, Taatjes DJ. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus. 2010; 19(4): 460-9

[165] RCOG 2010 Management of severe preeclampsia and eclampsia. Guideline No 10(A) March 2006 Reviewed 2010

[166] Redman CW, Sargent IL. Preeclampsia, the placenta and the maternal systematic inflammatory response- a review. Placenta 2003; 24 (Suppl 1): 921-27

[167] Redman CW, Sargent IL. Preeclampsia, the placenta and the maternal systematic inflammatory response- a review. Placenta 2003; 24 (Suppl 1): 921-27

[168] Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. American Journal of Obstetrics and Gynecology.2000;183:S1-S22

[169] Report of the National High Blood Pressure Education Program. Working group report on high blood pressure in pregnancy. Am J Obstet Gynecol 2000; 183:s1-22

[170] Rey E, Garnean P et al. Dalteparin for the prevention of recurrence of placenta-medicated complications of pregnancy in women without thrombophilia: a pilot randomized coutrolled trial. J. Thromb.Haemost. 2009; 7(1): 58-64

[171] Richter C, Sitzmann J, Lang P et al. Excretion of low molecular weight heparin in human milk // Br J Clin Pharmacol. 2001 Dec;52(6):708-10

[172] Riyazi N, Leeda M et al. Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. Eur. J. Obste.Gynecol.Reprod. Biol. 1998; 80 (1): 49-54

[173] Riyazi N, Leeda M, de Vries JI, Huijgens PC, van Geijn HP, Dekker GA. Low molecular weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth retriction: a preliminary study // Eur J Obstet Gynecol Reprod Biol. 1998;80: 49-54.

[174] Robertson L, Wu O, Langhorne P et al. Thrombophilia in pregnancy: a systematic review. Br. J. Haematol .2005; 132: 171-96

[175] Rodger MA, Betancourt MT, Clark P et al. The association of factor V leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies // PLoS Med. 2010 Jun 15;7(6):e1000292

[176] Rodger MA, Carrier M, Keely E, et al. The management of thrombophilia during pregnancy: a Canadian survey // J Obstet Gynaecol Can. 2002; 24:946-952.

[177] Rosendaal F.R. et al. Estrogens, Progesterons and Thrombosis. J.

Thromb.Hemost. 2003; 1: 1371-80

[178] Rosendaal F.R. et al. Estrogens, Progesterons and Thrombosis. J.

Thromb.Hemost. 2003; 1: 1371-80

[179] Saftlas AF, Olson DR, Atrash HK, et al. National trends in the incidence of abruptio placentae, 1979-1987 // Obstet Gynecol 1991;78:1081-6.

[180] Salmon JE, Girardi G. Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation // J Reprod Immunol. 2008 Jan;77(1):51-6. (199)

[181] Sanson BJ, Friederich PW, Simioni P, et al. The risk of abortion and stillbirth in antithrombin, protein C, and protein S-deficient women // Thromb Haemost. 1996;75: 387-388.

[182] Sanson BJ, Lensing AW, Prins MH et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review // Thromb Haemost. 1999 May;81(5):668-72.

[183] Sarig G, Lanir N, Hoffman R, Brenner B. Protein C global assay in the evaluation of women with idiopathic pregnancy loss // Thromb.Haemost.2002;88: 32-36.

[184] Saving Mothers. Third Report on Confidential Enquiries into Maternal Deaths in South Africa 2002-2004. Department of Health, Pretoria, Pretoria

[185] Schinner S, Scherbaum WA, Bornstein SR, Barthel A. Molecular mechanisms of insulin resistance. Diabetic Med 2005; 22:674-82

[186] Schlafke S, Enders AC. Cellular basis of interaction between throphoblast and uterus at implantation. Biol Reprod 1975; 12: 41-65

[187] Sheiner E, Shoham-Vardi I, Hadar A, Hallak M, Hackmon R, Mazor M. Incidence, obstetric risk factors and pregnancy outcome of preterm placental abruption: a retrospective analysis // J Matern Fetal Neonatal Med 2002;11:34

[188] Sibai B, Dekker G, Cupfermink M. Preeclampsia. Lancet 2005; 365(9461): 785-799

[189] Soleymanlon N et al. Molecular evidence of placental hypoxia in preeclampsia. J. Clin.Endocrinol.Metab. 2005; 90 (7): 4299-4308

[190] Sood R, Kalloway S, Mast AE et al. Fetomaternal cross talk in the placental vascular bed: control of coagulation by trophoblast cells // Blood. 2006 Apr 15;107(8):3173-80. (213)

[191] Soriano D, Carp H, Seidman DS et al. Management and outcome of pregnancy in women with thrombophylic disorders and past cerebrovascular events // Acta Obstet Gynecol Scand. 2002 Mar;81(3):104.

[192] Soriano D, Carp H, Seidman DS et al. Management and outcome of pregnancy in women with thrombophylic disorders and past cerebrovascular events // Acta Obstet Gynecol Scand. 2002 Mar;81(3):204-7.

[193] Steegers-Theunissen RP, Van Iersel CA, Peer PG et al. Hyperhomocysteinemia, pregnancy complications, and the timing of investigation // Obstet Gynecol. 2004 Aug;104(2):336-43

[194] Sugiura M. Pregnancy and delivery in protein C-deficiency // Curr Drug Targets. 2005 Aug;6(5):577-83.

[195] Tang CH, Wu CS, Lee TH et al. Preeclampsia-eclampsia and the risk of stroke among peripartum in Taiwan // Stroke. 2009 Apr;40(4):1162-8

[196] The European Genetics Foundation; I nt Angiol. 2005 Mar;24(1):1-26.

[197] Tincani A, Andreoli L, Casu C et al. Antiphospholipid antibody profile: implications for the evaluation and management of patients // Lupus. 2010

Apr;19(4):432-5.

[198] Turiel M, Sarzi-Puttini P, Peretti R et al. Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study // Stroke. 2005 Jul;36(7):1490-4.

[199] Ubbink JB, Becker PJ, Vermaak WJ, Delport R. Results of B-vitamin supplementation study used in a prediction model to define a reference range for plasma homocysteine // Clin Chem. 1995 Jul;41(7):1033-7.

[200] Unal S, Gumruk F, Aytac S et al. Interleukin-6 (IL-6), tumor necrosis factoralpha (TNF-alpha) levels and IL-6, TNF-polymorphisms in children with thrombosis// J Pediatr Hematol Oncol. 2008 Jan;30(1):26-31.

[201] Van der Molen EF, Verbruggen B, Novakova I, et al. Hyperhomocysteinenia and other thrombotic risk factors in women with placental vasculopathy // Br J Obstet Gynaecol. 2000;107: 785-791.

[202] Villar J, Abalos E, Nardin JM, Merialdi M, Carroli G. Strategies to prevent and treat preeclampsia: evidence from randomized controlled trials. Semin Nephrol 2004; 24(6): 607-15

[203] Vollset SE, Refsum H, Irgens LM, et al. Plasma total homocysteine pregnancy complications and adverse pregnancy outcomes: the Hordaland Homocysteine study // Am J Clin Nutr. 2000;7: 962-968.

[204] von Dadelszen P, Magee LA, Krajden M, Alasaly K, Popovska V, Devarakonda RM, et al. Levels of antibodies against CMV and C. pneumonia are increase in early onset preeclampsia. BJOG 2003; 110:725-30

[205] Von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclamosia. Hypertens Preg 2003; 22:143-148

[206] Walch KT, Huber JC. Progesterone for recurrent miscarriage: truth and deceptions // Best Pract Res Clin Obstet Gynaecol. 2008 Apr;22(2):375-89.

[207] Walker J. Pre-eclampsia. Lancet 2000: 356(9237):1260-1265.

[208] Wiener-Megnagi Z, Ben-Shlomo I, Goldberg Y, Shalev E. Resistance to activated protein C and the Leiden mutation: high prevalence in patients with abruptio // Am J Obstet Gynecol. 1998;179: 1565-1567.

[209] Williams MA, Farrand A, Mittendorf R, Sorensen TK, Zingheim RW, O'Reilly GC. Maternal second trimester serum tumor necrosis factor-α-solub receptor p55 (sTNFp55) and subsequent risk of preeclampsia. Am J Epidemiol 1999; 149:323-329

[210] Wilton A, De Greef A, Shennan A. Rapid assessment of blood pressure in the obstetric day unit using Microlife MaM technology. Hypertens Pregnancy 2007; 26(1): 31-7

[211] Yao T., Yao H., Wang H: Diagnosis and treatment of nephritic syndrome during pregnancy. Chin Med J (Engl) 109: 471, 1996

[212] Yeo L., Ananth CV, Vintzeleos AM. Placental abruption // Gynecology and obstetrics. Vol.2 Hagerstown. Lippricott, Williams & Wilkins, 2003

[213] Yoshimura T, Ito M, Nakamura T, Okamura H. The influence of labor on thrombotic and fibrinolytic systems // Eur J Obstet Gynecol Reprod Biol. 1992 May 13;44(3):195-9.

[214] Younis JS, Samuellof A. Gestational vascular complications // Ballieres Best Pract Res Clin Haematol. 2003;16: 135-151.

[215] Zoller B., Garcia DF, Dahlback B. Thrombophilia as a multigenic disease. Haematologica 1999; 84:59-70